Hainan Poly Pharm (300630.SZ): Busulfex injection granted temporary approval by the US FDA.
PulicPharma (300630.SZ) announced that the company recently received a notification from the U.S. Food and Drug Administration (FDA)...
Hainan Poly Pharm (300630.SZ) announced that the company recently received temporary approval from the Food and Drug Administration (FDA) of the United States for the injection of Brivudine. The indication for this drug is the treatment of partial onset seizures in patients aged 1 month and older.
Related Articles
C HEALTH GP(08225) officially launches multiple AI-RWS research projects, leading the new track of "AI+ clinical research".
The comprehensive net asset value per share of WALNUT CAP (00905) at the end of August is approximately HK$0.289.
SUMMI(00756): The hearing has been postponed to October 6th.
C HEALTH GP(08225) officially launches multiple AI-RWS research projects, leading the new track of "AI+ clinical research".
The comprehensive net asset value per share of WALNUT CAP (00905) at the end of August is approximately HK$0.289.
SUMMI(00756): The hearing has been postponed to October 6th.
RECOMMEND
Hong Kong Stock Concept Tracker｜Oracle (ORCL.US) RPO Surge Ignites AI Computing Power Chain—Domestic Opportunities in Focus
11/09/2025
Southbound Capital Flows Shift: Profit-Taking on High-Flying Stocks and Accumulating Alibaba and Tence
11/09/2025
Anti-Involution Policies Deliver Results as August Price Indicators Improve
11/09/2025
